Pain & Inflammation: Scientific Research & Clinical Trials

Chronic Pain

Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.

The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain.

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.

Cannabinoids for neuropathic pain.

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.

Neuropathic orofacial pain: cannabinoids as a therapeutic avenue.

Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.

Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved.

Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.

Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.

Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.

Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity.

Cannabinoids in the management of difficult to treat pain.

Marijuana extract helps prevent chemo pain

Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats.

Inflammation

Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice.

Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

The endocannabinoid system: an emerging key player in inflammation.

Cannabinoids, endocannabinoids, and related analogs in inflammation.

Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation.

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.

Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.

Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor.

Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement.

Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death.

Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption.

Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.

Cannabinoids in clinical practice.

Protective effect of cannabidiol on hydrogen peroxide‑induced apoptosis, inflammation and oxidative stress in nucleus pulposus cells.

Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis.